What Happened to Surrozen, Inc.?
Ticker: SRZNSPAC Year: 2020Merger: 2021
Return
+152.4%
Current Price
$25.24
Peak Price
$210
Trust Size
$99M
Summary
Surrozen is a clinical-stage biotech company developing antibody-based therapies that selectively activate the Wnt signaling pathway for tissue repair and regeneration.
What Happened
Surrozen went public in 2022 through a merger with Consonance-HFW Acquisition Corp, a SPAC sponsored by Consonance Capital Management. The company is pioneering Wnt biology to develop treatments for liver, intestinal, and retinal diseases where tissue regeneration is needed. Surrozen has advanced multiple programs into clinical trials, and the stock has performed relatively well for a clinical-stage biotech SPAC.
Timeline
2020-10-26
S-1 Registration Filed
2021-07-15
Merger Proxy Filed (DEFM14A)